Letter | Published:

The S100A8–serum amyloid A3–TLR4 paracrine cascade establishes a pre-metastatic phase

Nature Cell Biology volume 10, pages 13491355 (2008) | Download Citation

Subjects

Abstract

A large number of macrophages and haematopoietic progenitor cells accumulate in pre-metastatic lungs1,2 in which chemoattractants, such as S100A8 and S100A9, are produced by distant primary tumours serving as metastatic soil3. The exact mechanism by which these chemoattractants elicit cell accumulation is not known. Here, we show that serum amyloid A (SAA) 3, which is induced in pre-metastatic lungs by S100A8 and S100A9, has a role in the accumulation of myeloid cells and acts as a positive-feedback regulator for chemoattractant secretion. We also show that in lung endothelial cells and macrophages, Toll-like receptor (TLR) 4 acts as a functional receptor for SAA3 in the pre-metastatic phase. In our study, SAA3 stimulated NF-κB signalling in a TLR4-dependent manner and facilitated metastasis. This inflammation-like state accelerated the migration of primary tumour cells to lung tissues, but this was suppressed by the inhibition of either TLR4 or SAA3. Thus, blocking SAA3–TLR4 function in the pre-metastatic phase could prove to be an effective strategy for the prevention of pulmonary metastasis.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2, 289–300 (2002).

  2. 2.

    et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820–827 (2005).

  3. 3.

    , , & Tumour-mediated lung metastasis. Nature Cell Biol. 8, 1369–1375 (2006).

  4. 4.

    The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev. 8, 98–101, (1989).

  5. 5.

    & New functions for the matrix metalloproteinases in cancer progression. Nature Rev. Cancer 2, 161–174 (2002).

  6. 6.

    , , & Serum amyloid A is a chemotactic agonist at FPR2, a low-affinity N-formylpeptide receptor on mouse neutrophils. Biochem. Biophys. Res. Commun. 270, 331–335 (2000).

  7. 7.

    , & Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood 101, 1572–1581 (2003).

  8. 8.

    , , , & Induction of human mammary-associated serum amyloid A3 expression by prolactin or lipopolysaccharide. Biochem. Biophys. Res. Commun. 301, 1030–1037 (2003).

  9. 9.

    & Rat tissues express serum amyloid A protein-related mRNAs. Proc. Natl Acad. Sci. USA 86, 1890–1894 (1989).

  10. 10.

    , & Murine serum amyloid A3 is a high density apolipoprotein and is secreted by macrophages. Proc. Natl Acad. Sci. USA 89, 7949–7952 (1992).

  11. 11.

    & Functional analysis of a minimal mouse serum amyloid A3 promoter in transgenic mice. Amyloid 8, 250–256 (2001).

  12. 12.

    et al. Hyperglycemia-induced production of acute phase reactants in adipose tissue. J. Biol. Chem. 276, 42077–42083 (2001).

  13. 13.

    , & Tumor necrosis factor induces serum amyloid A3 in mouse granulosa cells. Endocrinology 145, 2245–2252 (2004).

  14. 14.

    et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 65, 5009–5014 (2005).

  15. 15.

    & Endotoxin (LPS) stimulates in vitro migration of macrophages from LPS-resistant mice but not from LPS-sensitive mice. J. Immunol. 128, 608–613 (1982).

  16. 16.

    Toll-like receptors: how they work and what they do. Curr. Opin. Hematol. 9, 2–10 (2002).

  17. 17.

    et al. Cell activation by Porphyromonas gingivalis lipid A molecule through Toll-like receptor 4- and myeloid differentiation factor 88-dependent signaling pathway. Int. Immunol. 14, 1325–1332 (2002).

  18. 18.

    , , , & RP105, a novel B cell surface molecule implicated in B cell activation, is a member of the leucine-rich repeat protein family. J. Immunol. 154, 3333–3340 (1995).

  19. 19.

    et al. Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14. J. Exp. Med. 198, 1035–1042 (2003).

  20. 20.

    et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Natue Med. 13, 1042–1049 (2007).

  21. 21.

    & Toll-lke receptor signaling. Nature Rev. Immunol. 4, 499–511 (2004).

  22. 22.

    Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430, 257–263 (2004).

  23. 23.

    et al. HSP70 as endogenous stimulus of the Toll/Interleukin-1 receptor signal pathway. J. Biol. Chem. 277, 15107–15112 (2002).

  24. 24.

    et al. Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. J. Exp. Med. 195, 99–111 (2002).

  25. 25.

    et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nature Med. 11, 1173–1179 (2005).

  26. 26.

    , & Fibrinogen stimulates macrophage chemokine secretion through Toll-like receptor 4. J. Immunol. 167, 2887–2894 (2001).

  27. 27.

    Cancer research. Inflammation and cancer: the link grows stronger. Science 306, 966–968 (2004).

  28. 28.

    et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118, 285–296 (2004).

  29. 29.

    et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to Lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol. 162, 3749–3752 (1999).

  30. 30.

    et al. A general strategy for isolation of endothelial cells from murine tissues. Characterization of two endothelial cell lines from the murine lung and subcutaneous sponge implants. Arterioscler. Thromb. Vasc. Biol. 17, 1599–1604 (1997).

Download references

Acknowledgements

We thank P. E. Scherer for providing the anti-mouse SAA3 antibody and pGEX-SAA3 vector, and T. Noda for preparation of the VEGFR1TK−/− mouse. We are grateful to B. Panda for checking the manuscript and also O. N. Witte for critical reading of manuscript and providing comments. This study was partly supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, 12147210 (Y.M.) and 16101006 (H.A.) the NIBIO program and NFAT project of New Energy and Industrial Technology Development Organization (H.A.) and Uehara foundation (S.H.)

Author information

Affiliations

  1. Department of Pharmacology, Tokyo Women's Medical University School of Medicine, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan.

    • Sachie Hiratsuka
    • , Yoshiko Sakurai
    • , Sachie Ishibashi
    •  & Yoshiro Maru
  2. Genome Science Division, Research Center for Advanced Science and Technology, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8904, Japan.

    • Akira Watanabe
    •  & Hiroyuki Aburatani
  3. Division of Infectious Genetics, Department of Microbiology and immunology, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.

    • Sachiko Akashi-Takamura
    •  & Kensuke Miyake
  4. Division of Genetics, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.

    • Masabumi Shibuya
  5. Department of Host Defense, Research Institute for Microbial Disease, Osaka University, 3-1 Yamada-oka, Suita, Osaka 565-1871, Japan.

    • Shizuo Akira

Authors

  1. Search for Sachie Hiratsuka in:

  2. Search for Akira Watanabe in:

  3. Search for Yoshiko Sakurai in:

  4. Search for Sachiko Akashi-Takamura in:

  5. Search for Sachie Ishibashi in:

  6. Search for Kensuke Miyake in:

  7. Search for Masabumi Shibuya in:

  8. Search for Shizuo Akira in:

  9. Search for Hiroyuki Aburatani in:

  10. Search for Yoshiro Maru in:

Contributions

S.H., Y.S. mainly contributed to animal studies; A.W. and S.I. contributed to molecular analysis; S.A.T., K.M., M.S. and S.A. supplied animals and materials; Y.M. designed and organized the work; H.A. and Y.M. supervised the work.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Yoshiro Maru.

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    Supplementary Information

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/ncb1794

Further reading Further reading